Literature DB >> 30392781

Improving outcomes in non-small cell lung cancer; population analysis of radical radiotherapy.

Michael Brada1, Christine Ball2, Susan Mitchell2, Helen Forbes3, Susan Ashley4.   

Abstract

AIM: Regional utilisation of radical radiotherapy (RT) in non-small cell lung cancer (NSCLC) was used to define optimal utilisation to improve outcome and as a surrogate for evidence of RT efficacy. PATIENTS &
METHODS: 65,412 NSCLC cases diagnosed in England 2012-13 were linked to comprehensive national radiotherapy dataset, hospital admissions and the Office of National Statistics. Geographical variation in utilisation was determined using a multivariate binary logistic regression analysis after adjusting for age, stage, deprivation, comorbidity and other radical treatment and the effect of radical RT utilisation on survival was investigated. Survival was adjusted for dependent and independent variables and the effect of differing levels of utilisation was assessed by the log likelihood test.
RESULTS: 17.6% cases potentially eligible for radical RT (stages 0-III) received radiotherapy with radical intent. Utilisation of radical RT had an impact on survival (p < 0.00001). Adjusting for all prognostic and treatment variables counties with lowest utilisation (≤15%) had the worst survival (HR = 1.13). The highest utilisation quintile counties (≥25%) had worse survival compared to counties with lower utilisation (≈20%) (p < 0.0001). Analysis of stages II&amp;III showed the same pattern; increase in utilisation from 20% to ≥25% resulting in a 3% drop in 2-year population survival (p = 0.001).
CONCLUSION: The utilisation of radical RT has a significant impact on NSCLC population survival. Improvement in survival of NSCLC population can be achieved by offering radical RT to a larger proportion of patients while avoiding excessive use. Geographical variation in RT utilisation provides indirect evidence of survival benefit of radical radiotherapy.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Big data; Dose fractionation; Non-small cell lung cancer; Radical radiotherapy; Radiotherapy utilisation

Mesh:

Year:  2018        PMID: 30392781     DOI: 10.1016/j.radonc.2018.10.015

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  3 in total

Review 1.  What is the optimal radiotherapy utilization rate for lung cancer?-a systematic review.

Authors:  Wei Liu; Alissa Liu; Jessica Chan; R Gabriel Boldt; Pablo Munoz-Schuffenegger; Alexander V Louie
Journal:  Transl Lung Cancer Res       Date:  2019-09

2.  Identification and Prognostic Value Exploration of Radiotherapy Sensitivity-Associated Genes in Non-Small-Cell Lung Cancer.

Authors:  Qing Ma; Kai Geng; Ping Xiao; Lili Zeng
Journal:  Biomed Res Int       Date:  2021-09-02       Impact factor: 3.411

3.  Optimal and actual rates of Stereotactic Ablative Body Radiotherapy (SABR) utilisation for primary lung cancer in Australia.

Authors:  Wsam Ghandourh; Lois Holloway; Vikneswary Batumalai; Phillip Chlap; Matthew Field; Susannah Jacob
Journal:  Clin Transl Radiat Oncol       Date:  2022-03-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.